Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026)
Immix Biopharma (IMMX) reported Capital Expenditures of $32486.0 for Q1 2026, down 52.02% on a YoY basis from $67713.0 in Q1 2025, and down 80.33% sequentially from $165126.0 in Q4 2025.
Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 5 years of Capital Expenditures data on file, last reported at $32486.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 52.02% year-over-year to $32486.0; the trailing twelve-month figure through Mar 2026 stood at $697698.0 (down 26.05% YoY), and the FY2025 full-year result was $732925.0, down 37.77% from the prior year.
- Capital Expenditures slipped to $32486.0 in Q1 2026, from $165126.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $507151.0 in Q4 2024 to a low of $13177.0 in Q4 2023.
- A 4-year average of $195626.8 and a median of $146378.0 in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures jumped 3748.76% in 2024 and tumbled 77.57% in 2025, its largest moves.
- Tracing IMMX's Capital Expenditures over 4 years: stood at $13177.0 in 2023, then jumped by 3748.76% to $507151.0 in 2024, then tumbled by 67.44% to $165126.0 in 2025, then slumped by 80.33% to $32486.0 in 2026.
- Business Quant data shows IMMX's Capital Expenditures at $32486.0 in Q1 2026, $165126.0 in Q4 2025, and $372456.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - | 32,486.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,486.00 |
| Mar 31, 2026 | 32,486.00 |
| Dec 31, 2025 | 165,126.00 |
| Dec 31, 2025 | 165,126.00 |
| Sep 30, 2025 | 372,456.00 |
| Sep 30, 2025 | 372,456.00 |
| Jun 30, 2025 | 127,630.00 |
| Jun 30, 2025 | 127,630.00 |
| Mar 31, 2025 | 67,713.00 |
| Mar 31, 2025 | 67,713.00 |
| Dec 31, 2024 | 507,151.00 |
| Dec 31, 2024 | 507,151.00 |
| Sep 30, 2024 | 271,542.00 |
| Sep 30, 2024 | 271,542.00 |
| Jun 30, 2024 | 97,074.00 |
| Jun 30, 2024 | 97,074.00 |
| Mar 31, 2024 | 301,913.00 |
| Mar 31, 2024 | 301,913.00 |
| Dec 31, 2023 | 13,177.00 |
| Dec 31, 2023 | 13,177.00 |